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Aims To examine the changes in coronary, all-cause, and cancer mortality in patients with heterozygous familial hyperch-
olesterolaemia (FH) before and after lipid-lowering therapy with statins.
Methods
and results
A total of 3382 patients (1650 men) aged ,80 years were recruited from 21 lipid clinics in the United Kingdom and
followed prospectively between 1980 and 2006 for 46 580 person-years. There were 370 deaths, including 190 from
coronary heart disease (CHD) and 90 from cancer. The standardized mortality ratio (compared with the population
in England and Wales) was calculated before and from 1 January 1992. In patients aged 20–79 years, CHD mortality
fell signiﬁcantly by 37% (95% CI ¼ 7–56) from 3.4- to 2.1-fold excess. Primary prevention resulted in a 48%
reduction in CHD mortality from 2.0-fold excess to none, with a smaller reduction of nearly 25% in patients with
established disease. Coronary mortality was reduced more in women than in men. In patients without known
CHD at registration, all-cause mortality from 1992 was 33% (21–43), lower than in the general population,
mainly due to a 37% (21–50) lower risk of fatal cancer.
Conclusion The results emphasize the importance of early identiﬁcation of FH and treatment with statins.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Familial hypercholesterolaemia (FH) is an autosomal co-dominant
disorder.
1 Defects in at least three different genes that code for
proteins involved in hepatic clearance of low-density
lipoprotein-cholesterol (LDL-C) can cause FH. These include,
mostcommonly,mutationsinthegenecodingfortheLDL-receptor
that removes LDL,
2 much less commonly in the gene for
Apolipoprotein B which is the major protein of the LDL particle,
and rarely in the gene coding for an enzyme called PCSK9
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doi:10.1093/eurheartj/ehn422involved in degrading the LDL receptor.
3 In all cases, this results in
an accumulation of LDL in the plasmafrom birth, and to subsequent
development of tendon xanthomas, xanthelasmas, and atheroma.
1
In the heterozygous condition, the cumulative risk of a coronary
e v e n tb yt h ea g eo f6 0y e a r sw i t h o u te f f e c t i v et r e a t m e n ti sa tl e a s t
50% in men and 30% in women. Coronary disease occurs 10
y e a r se a r l i e ri nm e nt h a ni nw o m e n ,w i t ham a r k e di n c r e a s ei n
women post-menopausally.
4–6 Before effective treatment with
HMG-Co reductase inhibitors (statins) became available, mortality
from coronary disease was increased nearly 100-fold in young adults
aged 20–39 years, and 4-fold for patients aged 40–59 years, but
in those surviving through middle age risk was similar to the high
rates of CHD in the general population of England and Wales.
7,8
In most European populations, heterozygous FH affects about one
in 500 individuals, but no randomized placebo-controlled clinical
outcome trials of statin treatment have been conducted for ethical
reasons. Clinical management is therefore largely based on extrapol-
ation from the results of cholesterol-lowering trials conducted in
patients with polygenic hypercholesterolaemia;
8 from evidence using
carotid intima-medial thickness as a surrogate outcome;
9 and from a
small number of prospective observational studies. The latter
include the Simon Broome Register of Familial Hyperlipidaemia,
which is a register of patients with heterozygous FH recruited from
21 lipid clinics in Great Britain.
7 Earlier results from the register
suggested that the prognosis for the heterozygous condition had
improved since the introduction and widespread use of statins.
10
The aim of this paper was to extend our previous reports
7,10–13
by studying an enlarged cohort of 3382 heterozygous patients fol-
lowed for up to 26 years until the end of 2006, by when the
exposure had more than doubled to 46 580 person-years. This
has allowed us to examine more informatively the changes in mor-
tality compared with the general population both before and after
the routine use of statins.
Methods
Patients and study design
The methods have been described previously.
7 Recruitment to the Simon
BroomeRegisterofpatientswith heterozygousfamilialhypercholesterola-
mia began since 1980s. Homozygous patients were excluded. The 21 par-
ticipating clinics registered patients referred to them by either general
practitioners or hospital specialists. Patients were classiﬁed as having
either ‘deﬁnite’ or ‘possible’ familial hypercholesterolaemia. A diagnosis
of deﬁnite familial hypercholesterolaemia in adults was deﬁned as a pre-
treatmentorontreatmenttotalcholesterol .7.5 mmol/L (or, when avail-
able, an LDL-C of .4.9 mmol/L) together with the presence of tendon
xanthomata either in the patient or in a parent, child, grandparent,
sibling, uncle, or aunt. Possible familial hypercholesterolaemia was
deﬁned using the same cholesterol criteria together with either a family
history of myocardial infarction before age 50 in second degree relative
or before age 60 in ﬁrst degree relative or, alternatively, a family history
of raised the total cholesterol concentration .7.5 mmol/L in the ﬁrst or
second degree relative. The original deﬁnition was subsequently
amended so that deﬁnite familial hypercholesterolaemia could be
deﬁned by the elevated cholesterol concentration and evidence of an
LDL-receptor,anApoBorPCSK9mutation,butforthisanalysistheclinical
criteria were used exclusively.
Registration and follow-up
The demographic and clinical characteristics of patients, including the
presence of tendon xanthomas, were recorded on a standard regis-
tration form. A fasting venous blood specimen was taken at the regis-
tration visit and serum total cholesterol, triglycerides, and high-density
lipoprotein were measured by the laboratories routinely used by the
participating clinics. Serum low-density lipoprotein concentrations
were calculated using the Friedewald formula.
14 The names of regis-
tered patients were ﬂagged by the National Health Service Central
Registry and, in the event of death, a copy of the death certiﬁcate
was provided. The underlying cause of death was coded by one inves-
tigator using the International Classiﬁcation of Disease (ICD), 9th
revision.
Statistical methods
The analysis was undertaken using a computer program for cohort
studies that applies standard methods.
15 Person-years of risk were
accumulated within 5 year age groups and 5 year calendar periods
to estimate the expected number of deaths from speciﬁed causes. A
total of 199 subjects were censored on reaching the age 80 years,
and a further 27 patients who had emigrated were censored at the
date of embarkation. The expected number of deaths from coronary
heart disease (CHD) (ICD codes 4100-4149), stroke (4300-4389),
non-coronary causes (10-4099 and 415-9999), cancers (1400-2089),
site-speciﬁc cancers, accidents and violence (8000-9999), and total
mortality were calculated by applying the age- and calendar-speciﬁc
death rates for men and women in the general population of
England and Wales to the person-years accumulated by men and
women in the cohort. The standardized mortality ratio (SMR) was
derived from the ratio of the number of deaths observed to those
expected, which was expressed as a percentage (SMR ¼ 100 for the
reference population), and the exact 95% conﬁdence intervals were
calculated. The test of signiﬁcance used was a two-sided Poisson prob-
ability of observing the number of deaths that occurred given the
expected number of deaths. Separate analyses for mortality were
undertaken for the periods up to and from 1 January 1992 by which
date statins were being widely prescribed.
Results
A total of 3413 patients were registered between 1 January 1980
and 31 December 2006. We excluded 28 (0.8%) patients whose
vital status was unknown and three patients aged .80 years at
registration. The resulting cohort of 3382 patients (1650 men)
was followed for 46 580 person-years with a median duration of
follow-up of 14.5 years for men and 14.1 years for women. It
consisted of 1842 patients (908 male) with deﬁnite familial
hypercholesterolaemia and 1540 patients (742 male) with possible
familial hypercholesterolaemia who were followed for 25 504 and
21 076 person-years, respectively.
Patient characteristics
Table 1 describes the clinical characteristics, and reports the mean
serum lipid and lipoprotein concentrations at registration for men
and women (denominators differ because of missing measure-
ments). By registration, 94.7% of patients (3184/3361) had received
dietary advice and 54.6% (1568/2871) had already been prescribed
lipid-lowering drug therapy. However, before treatment, the mean
total cholesterol concentration was 9.5 (SD 2.0) mmol/L for men
A. Neil et al. 2626(n ¼ 1409) and 9.8 (2.1) mmol/L for women (n ¼ 1515). At regis-
tration, 28% of men and 19.5% of women had known CHD deﬁned
as either a history of a previous myocardial infarction, angina, a
coronary artery by-pass graft, or angioplasty.
Deaths by major cause and time period
Table 2 shows the observed and expected number of deaths by
major cause and time period. In total, there were 370 deaths
from all causes. There was a signiﬁcant excess in mortality from
all causes before, but not after, 1 January 1992. There were no
differences in the observed and expected numbers of deaths
from stroke or from accidents and violence in either period, but
non-coronary mortality was signiﬁcantly lower than the expected
in both time periods (SMR 61 and 62, respectively). There were
90 deaths from cancer with no signiﬁcant reduction in the ﬁrst
time period, but a 37% (95% CI ¼ 21–50) lower than the
expected cancer mortality in the second period. In total, there
were 190 coronary deaths, and the SMR fell signiﬁcantly by 37%
(95% CI ¼ 7–56; P ¼ 0.01) in the second period from 3.4 - to
2.1-fold excess.
Standardized mortality ratio for coronary
heart disease
Table 3 gives the observed and expected number of deaths from
CHD by age group and time period for patients with and without
known coronary disease at registration. No data are shown for
patients aged ,20 years (2223 person-years exposure) because
no fatal events were observed. For secondary prevention, there
was a reduction in SMR of 25% from a 5.2 (95% CI ¼ 3.4–7.6) to
a 3.9-fold excess (95% CI ¼ 3.2–4.7) with a larger reduction in
women than in men (51 vs. 8%, data not shown). For primary pre-
vention, there was a 48% reduction in SMR from a 2-fold excess in
mortalitytonone.Therewasalargereductionincoronarymortality
in patients aged 20–39 years from a 37-fold excess to an 11.5-fold
excess, and for those aged 40–59 years there was a reduction of
...............................................................................................................................................................................
Table 1 Clinical characteristics at registration
Men (n 5 1650) Women (n 5 1732)
Median age (inter-quartile range) 43.1 (31.9, 52.2) 49.0 (32.7, 59.7).
Previous myocardial infarction 247 (15.1%, n ¼ 1632) 119 (6.9%, n ¼ 1716)
Current or past angina 330 (20.3%, n ¼ 1623) 283 (16.5%, n ¼ 1716)
Diagnosed coronary heart disease 462 (28.0%, n ¼ 1649) 338 (19.5%, n ¼ 1732)
Previous stroke 21 (1.3%, n ¼ 1629) 22 (1.3%, n ¼ 1718)
Diagnosed diabetes 24 (1.5%, n ¼ 1630) 20 (1.2%, n ¼ 1717)
Current cigarette smoker 269 (16.6%, n ¼ 1622) 340 (19.6%, n ¼ 1732)
Systolic blood pressure (mmHg) 129.8 (18.8, n ¼ 1535) 134.2 (22.6, n ¼ 1632)
Diastolic blood pressure (mmHg) 79.6 (11.2, n ¼ 1535) 80.5 (11.7, n ¼ 1632)
Body mass index (kg/m
2) 25.2 (4.4, n ¼ 1424) 24.79 (4.6, n ¼ 1525)
Body mass index (kg/m
2)  30 143 (10.0%, n ¼ 1424) 194 (12.7%, n ¼ 1525)
Total cholesterol (mmol/l) 7.9 (1.9, n ¼ 1592) 8.2 (2.1, n ¼ 1678)
Triglycerides (mmol/L, geometric mean and inter-quartile range) 1.5 (1.0, 2.3, n ¼ 1555) 1.3 (0.9, 1.9, n ¼ 1639)
High-density lipoprotein-cholesterol (mmol/L) 1.2 (0.3, n ¼ 1341) 1.4 (0.38, n ¼ 1429)
Low-density lipoprotein-cholesterol
a (mmol/L) 5.8 (1.9, n ¼ 1268) 6.1 (2.1, n ¼ 1388)
Results are presented as mean (SD) unless otherwise stated.
Diagnosed CHD deﬁned as a previous myocardial infarction, angina, coronary artery by-passgraft, or angioplasty.
aLDL-cholesterol concentrations were calculated according to Friedewald et al.
14
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Table 2 Observed and expected deaths by major cause and time period
From 1 January 1980 to 31 December 1991
(person-years exposure 5 6640 years)
From 1 January 1992 (person-years
exposure 5 37 726 years)
Observed Expected SMR 95% CI P-value Observed Expected SMR 95% CI P-value
Coronary heart disease 37 10.93 339 238–467 ,0.0001 153 71.68 213 181–250 ,0.0001
Stroke 1 2.81 36 1–198 0.46 20 24.59 80 47–128 0.43
Non-coronary heart disease 18 29.27 61 36–97 0.04 162 262.34 62 53–72 ,0.0001
Accidents and violence 1 2.32 43 1–240 0.65 7 9.38 75 30–154 0.56
All cancers 14 14.56 96 53–161 1 76 120.44 63 50–79 ,0.0001
All-causes of death 55 40.2 137 103–178 0.03 315 334.02 94 84–105 0.31
Familial hypercholesterolaemia: changes in mortality with statins 2627........................................................................................ ................................................................................
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Table 3 Observed and expected deaths from coronary heart disease by age group and time period for patients with and without known coronary disease at
registration
Attained
age
(years)
Person-years
observation
1 January 1980 to 31 December 1991 Person-years
observation
1 January 1992 to 31 December 2006
Observed Expected SMR 95% CI P-value Rate/
100 000
Observed Expected SMR 95% CI P-value Rate/
100 000
Primary prevention
20–39 2031 3 0.08 3750 773–10 959 ,0.001 148 8227 3 0.26 1153 238–3372 ,0.01 37
40–59 2181 8 2.34 342 148–674 ,0.01 367 13123 13 9.19 141 75–242 0.28 99
60–79 686 1 3.63 27 1–153 0.25 146 8219 29 34.33 84 57–121 0.41 353
20–79 4898 12 6.05 198 102–346 0.04 212 29 569 45 43.78 103 75–138 0.89 145
Secondary prevention
20–39 178 5 0.01 50000 16 235–116 683 ,0.0001 2816 229 1 0 0 436
40–59 1016 9 1.58 570 260–1081 ,0.0001 886 3419 34 3.83 888 615–1241 ,0.0001 995
60–79 539 11 3.24 340 169–607 ,0.001 2038 4509 73 24.01 304 238–382 ,0.0001 1619
20–79 1733 25 4.83 515 335– 764 ,0.0001 1442 8157 108 27.84 388 318–468 ,0.0001 1324
................................................................................. ..................................................................................
.............................................................................................................................................................................................................................................
Table 4 Observed and expected deaths from coronary heart disease for men and women without known coronary disease at registration from 1 January 1992 until
31 December 2006
Attained
age (years)
Person-years
observation
Men Person-years
observation
Women
Observed Expected SMR 95% CI P-value Rate/
100 000
Observed Expected SMR 95% CI P-value Rate/
100 000
20–39 4120 2 0.23 870 105–3141 0.045 49 4107 1 0.03 3333 84–18 572 0.059 24
40–59 7068 12 7.56 159 82–277 0.17 170 6054 1 1.63 61 2–342 1 17
60–79 2529 11 15.98 69 34–123 0.26 435 5690 18 18.35 98 58–155 1 316
20–79 13 717 25 23.77 105 68–155 0.85 172 15 851 20 20.01 100 61–154 1 121
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859% from a 3.4-fold signiﬁcant excess to a 1.4-fold non-signiﬁcant
excess mortality. Overall, for primary and secondary prevention
combined, for women there was a 60% reduction in SMR from
4.2- to 1.7-fold excess (P ¼ 0.001), and for men an 18% reduction
from 3.0 to 2.4-fold excess (P ¼ ns). The SMR fell signiﬁcantly by
34%(from384to 255)inpatients withdeﬁnitefamilialhypercholes-
terolaemia (P ¼ 0.05) and non-signiﬁcantly by 37% (from 270 to
171) in patients with possible familial hypercholesterolaemia (data
not shown). Table 4 shows that for primary prevention there was
no longer a statistically signiﬁcant excess coronary mortality for
either men or women aged 40 years or more.
Standardized mortality ratio
for all-causes and cancer
Table 5 shows the observed and expected numbers of deaths from
all-causes by age group and time period for patients with and
without known coronary disease at registration. It demonstrates
that for primary prevention from 1992 there was no excess all-
cause mortality under the age of 60 years and a 43% signiﬁcantly
lower mortality in patients aged 60–79 years. For secondary pre-
vention, the all-cause mortality was elevated in both time periods.
Table 6 presents a combined analysis for men and women of all
cancer and site-speciﬁc cancer mortality. There was a statistically sig-
niﬁcant 37% reduction in all cancer mortality (95% CI ¼ 21–50)
after, but not before, 1 January 1992. A site-speciﬁc analysis
showed that after this date there were signiﬁcant reductions of
73% for fatal cancers of the respiratory and intrathoracic organs;
78% for lymphatic and haemopoetic cancer, 49% for genitourinary
cancers, and a borderline signiﬁcant reduction of 39% for digestive
and peritoneal cancers. A record of past cigarette smoking was avail-
able for 97% (3266/3382) of patients, and 71% of those dying of
cancer (62/87) compared with 43% (1366/3179) of the remainder
had ever smoked (hazard ratio 3.47; 95% CI ¼ 2.2–5.7;
P , 0.0001). From 1992, deaths from respiratory causes other
than cancer (ICD codes 460-519) were 63% (95% CI ¼ 37–80;
P , 0.0001) lower than in the general population (data not shown).
Discussion
Principal ﬁndings
This large long-term prospective registry study of 3382 patients
with heterozygous familial hypercholesterolaemia demonstrates a
statistically signiﬁcant reduction in coronary mortality of about
one-third since the widespread use of statins. Primary prevention
resulted in a halving in risk of fatal coronary events, with a
smaller reduction of nearly one-quarters in patients with estab-
lished disease. Mortality was reduced more in women than in
men for both primary and secondary prevention. Importantly, in
patients without known coronary disease at registration, all-cause
mortality was signiﬁcantly lower than in the general population,
mainly due to a reduction of more than one-thirds in the risk of
fatal cancer. The data also conﬁrm our earlier ﬁndings that FH
patients are not at a higher risk of fatal stroke.
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Familial hypercholesterolaemia: changes in mortality with statins 2629Comparison with other studies
Few comparable data are available, with the exception of a much
smaller prospective study from the Netherlands that used similar
diagnostic criteria.
16 It followed 345 statin-treated patients for up
to 8 years between 1988 and 1997. Among the 214 patients
without a history of cardiovascular disease, there were ﬁve ischae-
mic heart disease deaths and mortality was increased 2.6-fold for
patients of all ages with wide conﬁdence intervals (95% CI ¼
1.1–6.3) and 7.6-fold for patients aged 40–59 years (95% CI ¼
2.9–20). In contrast, for the period 1992 to 2006, we found no
excess coronary mortality for patients of all ages without known
coronary disease at registration and only a 1.4-fold non-signiﬁcant
increase for patients aged 40–59 years (95% CI ¼ 0.7–2.4).
Overall, in a combined analysis for primary and secondary preven-
tion, for men and women of all ages, coronary mortality was
reduced by 37% (P ¼ 0.01) when comparing the periods before
and after 1992, which is similar to the reduction in major coronary
events observed in randomized placebo-controlled trials of statin
therapy. However, the Cholesterol Treatment Trialists’ Collabor-
ators systematic prospective meta-analysis,
8 which reported the efﬁ-
cacy of cholesterol-lowering treatment using individual patient data
for 90 056 participants in 14 randomized trials of statins, found a
similar proportional reduction in major coronary events irrespective
of age, sex, or previous coronary disease. This differs from the
pattern of mortality evident in different sub-groups in our study.
Coronary mortality
We found that, before and after statins became widely available,
there was no excess coronary mortality in patients aged .60
years without known coronary disease at registration. This may
be explained by selective survival, with earlier death occurring in
those individuals most susceptible to the atherogenic effects of
raised LDL-C, and a correspondingly lower risk among survivors.
There is a strong intra-familial correlation for age of coronary
death
17 and differences in susceptibility will be related partly to
the particular mutation present.
18 A higher risk of coronary
disease in patients with LDL receptor null allele mutations and in
those with the PCSK9 (D374Y) mutation is well documented.
19,20
Other genetic polymorphisms, including apolipoprotein E, are
also associated with risk,
21 while some loss of function common
variants in the PCSK9 gene are associated with lower risk in the
general population
22 and possibly also in FH patients.
23 Conven-
tional cardiovascular risk factors such as gender, smoking, hyper-
tension, and high-density lipoprotein cholesterol are recognized
to inﬂuence the age of onset and severity of coronary disease in
heterozygous patients.
24–26 Patients surviving into older age
before statins became available were therefore likely to be a
highly selected group at lower risk of coronary disease. In contrast,
middle-aged patients were probably at more representative levels
of coronary risk and the observed 59% reduction in the SMR for
primary prevention in our cohort is consistent with the expected
beneﬁt of statin treatment. In the youngest group, aged 20–39
years, the number of events was small and the estimated mortality
ratios are imprecise but suggest that the relative reduction in
events may possibly be even larger.
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A. Neil et al. 2630The beneﬁt of secondary prevention after the introduction
and widespread use of statins appeared to be greater in
women than in men with a 51 and 8% reduction, respectively,
in the SMR. However, prior to 1992, these ﬁndings were
based on only 15 events in men and 10 in women, and need
to be interpreted with caution, particularly since the estimated
reductions in risk from 1992 were imprecise and not statistically
signiﬁcant. It is possible, however, that the beneﬁts of treatment
were less in men, because the onset of coronary disease occurs
10 years earlier than in women
4–6 and consequently men will
have had more extensive atheroma that may involve the coron-
ary ostia and aortic root, as well as the coronary arteries.
27 Fur-
thermore, the intensity of statin treatment may have been
sub-optimal, since evidence that reducing LDL-C by at least
50% in heterozygous FH prevents the progression of carotid
intima medial thickness was not published until 2001.
9 Achieving
substantial reductions in LDL was difﬁcult before the introduc-
tion of more potent statins,
28 which are now often used in
combination with a cholesterol absorption inhibitor to reduce
LDL further, although the clinical beneﬁt of combination
therapy has yet to be demonstrated.
29 The more widespread
use of post-infarction cardioprotective therapy with ACE inhibi-
tors, beta-blockers, and aspirin and coronary interventions over
the last 10–15 years would also be expected to have improved
the prognosis, but in our cohort men showed little apparent
beneﬁt.
All-cause and cancer mortalities
All-cause mortality was signiﬁcantly reduced by about one-third in
patients without known coronary disease at registration, which
was mainly due to a reduction in cancer mortality. This is probably
attributable to close adherence to advice given as part of routine
clinical care to be physically active, make dietary changes,
30 avoid
obesity,
31 and stop smoking. The reduction in cancer mortality
observed may also, in part, reﬂect earlier detection and treatment
of cancer among patients undergoing regular medical surveillance,
resulting in a better prognosis. It cannot be explained by competing
mortality from premature coronary disease since the reduction in
cancer mortality was only evident from 1992 onwards from when
there was no excess coronary mortality for patients without
known coronary disease at registration. The delay in the reduction
in mortality may be due to the prolonged lead-time between
exposure to carcinogens, pre-clinical incident disease, and sub-
sequent mortality. We cannot, however, entirely exclude the
possibility that statins have anti-cancer activity.
32 Indeed, a recent
Canadian retrospective study of 30 076 patients started on a lipo-
philic statin after a myocardial infarction reported a reduction of
one-quarter in the hazard ratio for cancer incidence with high-dose
statin treatment.
33 However, the ﬁndings from observational
studies are not supported by the results of a meta-analysis of
clinical outcome trials conducted by the Cholesterol Treatment
Trialists’ Collaboration which reported no reduction in cancer
incidence.
8 Nevertheless, their results cannot completely exclude
longer term effects of statins as the mean duration of these trials
was only 5 years.
Study limitations
Some care is needed in interpreting our ﬁndings. Although this is
the largest published cohort of patients with heterozygous familial
hypercholesterolaemia with over 44 000 person-years exposure in
adulthood, it has limited statistical power to examine differences in
mortality between the two time periods for multiple age- and sex-
speciﬁc sub-groups. Furthermore, although statin treatment has
been used routinely after 1991, some patients are likely to have
been prescribed statins earlier, although most received less efﬁca-
cious treatment with bile acid sequestrants, ﬁbrates, and occasion-
ally niacin. Our results are therefore likely to under-estimate the
maximum potential beneﬁts of statin treatment. It should also be
recognized that the cohort comprised patients referred to specialist
lipid clinics and cannot be entirely representative because at least
three-quarters of affected cases in the United Kingdom remain
undiagnosed.
34 The results are, therefore, of most direct relevance
to patients referred for specialist care which, in practice, includes
most patients in the community with diagnosed familial hypercholes-
terolaemia.
34 There are, however, no entirely satisfactory clinical
diagnostic criteria and some misclassiﬁcation of polygenic hyperch-
olesterolaemia as familial will have occurred,
35,36 particularly
among patients with possible familial hypercholesterolaemia, which
will result in an under-estimate in absolute rates of coronary mor-
tality. In contrast, DNA testing offers a deﬁnitive, highly speciﬁc diag-
nosis, which will be adopted in routine clinical practice as the speed
and sensitivity of mutation testing increases and cost decreases using
kits to test for common mutations
37 and systems such as those
based on a DNA microarray.
38 As this study has shown, the preva-
lence of other cardiovascular risk factors in this monogenic disorder
is no higher, and is probably lower, than in the general population,
and our analyses made no adjustment for them.
Clinical implications
Our ﬁndings have a number of clinical implications. The study con-
ﬁrms the importance of early identiﬁcation and treatment of
affected heterozygous individuals since the major beneﬁt of statin
treatment appears to be in the primary prevention of fatal coron-
ary disease. This suggests that with earlier diagnosis it should be
possible to prevent any excess coronary mortality in early adult-
hood. It supports a strategy of cascade testing to identify the
affected relatives of probands and, since LDL-C levels are elevated
from soon after birth, testing must include children who have the
highest rates of under-diagnosis.
34 Recent guidelines from the
American Academy of Pediatrics recommend treatment with a
statin from 8 years of age for children with a family history of
early heart disease and an LDL-C level of .4.1 mmol/L,
39 although
there is no clear evidence for this particular treatment threshold.
40
Our results also indicate that more intensive treatment may be
needed to reduce the coronary mortality in patients with estab-
lished disease, especially in men. In addition, the ﬁndings strongly
suggest that lifestyle factors are associated with a large reduction
in mortality from cancer, which in primary prevention results in
the overall mortality being lower than in the general population.
Lifestyle advice, therefore, remains an important aspect of care.
Longer term follow-up will be needed to assess the prognosis
into older age of patients treated with statins from early adulthood,
Familial hypercholesterolaemia: changes in mortality with statins 2631but expansion of the cohort would be needed to examine the long-
term safety and efﬁcacy of statin treatment started in childhood.
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Uncommon variation in the papillary muscles presenting with ST elevation
and T-wave inversion
Chi Young Shim, Jong-Won Ha, Sung Jin Hong, Jinsun Kim, Eui-Young Choi, Namsik Chung, and
Seung-Yun Cho*
Cardiology Division, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seodaemun Gu, 120-752 Seoul, Republic of Korea
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A 61-year-old woman was
admitted for intermittent
chest discomfort that had
been present for 2
months. She was normo-
tensive and denied any
past history of medical
illness. On physical exam-
ination, grade 2 systolic
click murmur at the left
ventricular (LV) apex was
auscultated. A routine
electrocardiogram (Panel
A) revealed ST-segment
elevation and T-wave
inversion in V2 to V5 pre-
cordial leads with high voltage of QRS complex which made us suspect possible hypertrophic cardiomyopathy. Two-dimensional
echocardiography showed no evidence of LV hypertrophy in all segments. However, unexpectedly, unusual structures of papillary
muscles were detected. The papillary muscles were interlinked each others with numerous ﬁne tendons and formed parallel arrange-
ment without hypertrophies (Panel B). The anterior mitral leaﬂet was mildly prolapsed without signiﬁcant mitral regurgitation. To
clarify the structures of papillary muscles, perﬂurocarbon-exposed sonicated dextrose albumin (PESDA), a pulmonary circulation
passing contrast agent, was injected via an antecubital vein. Contrast echocardiogram with PESDA showed contrast ﬁlling and opaci-
ﬁcation of the LV cavity showed more clearly the unusual variation of papillary muscles with four parallel bellies (Panel C). Coronary
angiography showed no signiﬁcant luminal narrowing (Panels D and E). A contrast-enhanced image obtained by magnetic resonance
imaging showed consistent ﬁndings in structures (Panel F) and no delayed hyperenhancement of four papillary muscles, so there was
no evidence of ﬁbrosis in the papillary muscles (Panel G). This case illustrates that the variations of the papillary muscles should be
considered for differential diagnosis of abnormal electrocardiographic ﬁndings such as ST elevation and T-wave inversion.
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